department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ciprofloxacin · pharmadog

pharmadog
drugs
Ciprofloxacin

drug

patient view →

ciprofloxacin

Marketedupdated 2mo ago

by Bedford Laboratories

Approved

community read0 votes

all catalysts(1)

phase 1 completion · 1

phase 1 completion

Johns Hopkins University — ciprofloxacin (Phase I Trial Completion)

News(0)

no news has mentioned this drug yet

brand

Ciprofloxacin

generic

ciprofloxacin

indication

Septic Arthritis

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 21, 2029

~2.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Nov 27, 2038formulationUS 11246863
Nov 12, 2037method-of-use (U-2252)US 11040004
Jul 1, 2035formulationUS 9220796
Apr 27, 2030method-of-use (U-1792)US 83188173.8y
Dec 11, 2029formulationUS 92330683.4y
Apr 21, 2029formulationUS 113695662.8y
Apr 21, 2029method-of-use (U-1793)US 92050482.8y
Apr 21, 2029compositionUS 96037962.8y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval94 co-mentions · 45 sources
drugciprofloxacin hydrochloride ER47 co-mentions · 44 sources
drugCIPROFLOXACIN HYDROCHLORIDE47 co-mentions · 44 sources
tagSmall Molecule43 co-mentions · 43 sources
tagRecall4 co-mentions · 4 sources
drugdexamethasone SR3 co-mentions · 2 sources
drugNEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE2 co-mentions · 1 sources
companyLeading Pharma LLC2 co-mentions · 2 sources

Trials studying ciprofloxacin

—Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
phase1A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566completedn=60
phase2Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Studycompletedn=210
phase2PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatmentnot yet recruitingn=206
phase2Ciprofloxacin BioThrax Co-Administration Studycompletedn=154
phase1A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjectscompletedn=64
N/ALiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Mediacompletedn=175
phase1Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mgcompletedn=36

more trials →